Guideline on the acceptability of names for human medicinal products processed through the centralised procedure

Current effective version	Revision 6 - Adopted guideline
Reference number	EMA/CHMP/287710/2014 – Rev. 6
Published	3 June 2014
Keywords	EMA, CHMP, NRG, invented name
Description	Based on the experience gathered by the Name Review Group (NRG) since the last revision of the guideline in December 2007, it became apparent that some areas of the guideline would benefit from further clarifications, in particular with regards to the requirements for acceptability and submission of proposed (invented) names of medicinal products processed through the centralised procedure. This 6th update of the guideline further clarifies specific aspects of the criteria applied to address safety and public health concerns, international non-proprietary names issues and product-specific concerns in proposed (invented) names. Also, the procedure for submission of proposed (invented) names requests is streamlined and further clarified.